Ikechi Nnawuchi
Psychiatry · Washington, DCNPI 1598798662
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $502,515 of the $623,580 with a category attached, or 80.6%. Neurocrine Biosciences, Inc. accounts for 65.9% of it on its own, with 14 other manufacturers making up the rest. Among psychiatry clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,540 payments — averaging $404.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$411K
- AbbVie$92K
- Otsuka America Pharmaceutical, Inc.$91K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$15K
- Sunovion Pharmaceuticals Inc.$4K
- Corium, LLC$2K
- plus $9K from 9 others
What the payments were for
- Consulting fees$33,5325%
- Speaking & faculty fees$502,51581%
- Travel & lodging$53,6729%
- Food & beverage$33,6305%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 469 | $410,713 |
| AbbVie(2 entities) | 200 | $91,807 |
| Otsuka America Pharmaceutical, Inc. | 163 | $90,604 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 112 | $15,224 |
| Sunovion Pharmaceuticals Inc. | 186 | $4,149 |
| Corium, LLC | 8 | $2,253 |
| Lundbeck LLC | 100 | $1,961 |
| Alkermes, Inc. | 80 | $1,691 |
| Vanda Pharmaceuticals Inc. | 55 | $1,417 |
| Johnson & Johnson | 53 | $1,395 |
| Teva Pharmaceuticals USA, Inc. | 68 | $1,142 |
| E.r. Squibb & Sons, L.L.C. | 38 | $914 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
| Indivior Inc. | 6 | $147 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$404,531
- VRAYLAR$89,043
- ABILIFY MAINTENA$60,855
- ABILIFY ASIMTUFII$57,878
- REXULTI$27,494
- CAPLYTA$13,069
- Azstarys$2,040
- ARISTADA$416
- COBENFY$231
- INVEGA SUSTENNA$149
- LATUDA$112
- ARISTADA INITIO$104
How this compares
$623,580 in reported general payments places this provider in the 95th percentile of 226 psychiatry providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 114 | $985,216 |
| Invega SustennaPaliperidone Palmitate | 74 | $194,081 |
| VraylarCariprazine Hcl | 53 | $79,164 |
| Abilify MaintenaAripiprazole | 25 | $64,709 |
| Abilify AsimtufiiAripiprazole | 11 | $56,280 |
| AristadaAripiprazole Lauroxil | 12 | $33,836 |
| Risperidone ErRisperidone Microspheres | 12 | $12,659 |
| Paliperidone ErPaliperidone | 32 | $8,765 |
| Haloperidol Decanoate | 154 | $8,467 |
| Benztropine Mesylate | 176 | $2,773 |
| Divalproex Sodium | 73 | $1,679 |
| Quetiapine Fumarate | 91 | $1,649 |
| Haloperidol | 36 | $1,597 |
| Oxcarbazepine | 31 | $1,234 |
| Bupropion XlBupropion Hcl | 60 | $1,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $410,713 | $985,216114 claims |
| Johnson & JohnsonInvega Sustenna | $1,395 | $194,08174 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii | $90,604 | $120,98936 claims |
| AbbVieVraylar | $91,807 | $79,16453 claims |
| Alkermes, Inc.Aristada | $1,691 | $33,83612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 psychiatry providers in District of Columbia.
Other psychiatry in Washington
- James GordonWashington$20K
- Thomas MellmanWashington$19K
- Tony GoreWashington$11K
- Dwight KingWashington$10K
- Igor VolkovWashington$10K
- Joel KleinmanWashington$8K
- Vivienne GomesWashington$6K
- Irfan SaeedWashington$6K
- Arda KasaciWashington$5K
- Todd AugustusWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.